Subgroup Analysis of ENGAGE AF-TIMI 48 explores the relationship between edoxaban dose, concentration, anti-factor Xa activity and outcomes
3 September 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced data from a subgroup analysis of the phase 3 ENGAGE AF-TIMI 48 study, that explores the relationship between edoxaban dose, concentration and anti-factor Xa activity in patients with non-valvular atrial fibrillation...